Nov-DB2 is under clinical development by NovMetaPharma and currently in Phase II for Type 2 Diabetes. According to GlobalData, Phase II drugs for Type 2 Diabetes have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nov-DB2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NovDB-2 is under development for the treatment of type 2 diabetes and obesity. It acts by targeting insulin-degrading enzyme (IDE). The drug candidate is a new chemical entity.
NovMetaPharma develops and distributes dietary products and novel drugs for the treatment of metabolic diseases. The company is investigating its lead pipeline candidate, Cyclo-Z, for the treatment of type 2 diabetes, and obesity; and another pipeline candidate for the treatment of Alzheimer’s disease. The company develops and distributes healthy dietary products. The company also collaborates with research institutes for advancing its therapeutic agents in the areas of metabolic diseases, diseases of immune system, osteoporosis, and non-alcoholic fatty liver. It has partnerships with CRO cooperation, POSTECH, and Department of Veterans Affairs (US). Novmetapharma is headquartered in Gangnam-gu, Seoul, Korea.
For a complete picture of Nov-DB2’s drug-specific PTSR and LoA scores, buy the report here.